Abstract 1776
Background
Mobile phones and tablets currently represent a significant presence in people’s everyday lives. They enable access to different information and services independent of current place and time. Such widespread connectivity offers significant potential in different app areas including health care. Advancements in mobile technology allow innovative data collection techniques such as measuring time use for the purpose of improving health behavior change interventions.
Methods
The aim of this study is to examine the usage rates of healthcare users and the health content of applications. A total of 707 mobile app were retrieved through a Google and App store for app published between January to April 2019. In this context, all applications were scanned using "cancer", "oncology", and "breast cancer" keywords on these stores. Repetitive applications were removed and research data was obtained. The applications were evaluated by considering their contents, developers and download numbers.
Results
In the Google play store, under the training title of 268 applications, it was found that 76 applications were used to maintain the treatment scheme and plan, and 12 were used for communication purposes. In the app store, it was determined that 235 applications were used for education, 102 for treatment plan and order, and 14 for communication purposes. Educational applications were used for journal, congress, student information, cancer guidelines and patient information. Drug management for treatment regimen and plan was determined to be related to radiological imaging, diet follow-up, symptoms, and nutrition. It was seen that communication applications were used for both patient-patient and physician-patient interaction. It was found that only 8% of the existing applications that the majority of the application developers did not have a healthcare staff established a health care staff.
Conclusions
It can be said that health personnel develop their own systems and provide accurate information to patients through these systems. With the advancement of health technologies, healthy results can be obtained in the near future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Aydanur Aydin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract